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High-throughput analysislection in multiple regression models in which molecular markers and/or gene-
expression measurements as well as intensity measurements from protein spectra serve as predictors for the
outcome variable (i.e., trait or disease state). Finding genetic biomarkers and searching genetic–
epidemiological factors can be formulated as a statistical problem of variable selection, in which, from a
large set of candidates, a small number of trait-associated predictors are identiﬁed. We illustrate our
approach by analyzing the data available for chronic fatigue syndrome (CFS). CFS is a complex disease from
several aspects, e.g., it is difﬁcult to diagnose and difﬁcult to quantify. To identify biomarkers we used
microarray data and SELDI-TOF-based proteomics data. We also analyzed genetic marker information for a
large number of SNPs for an overlapping set of individuals. The objectives of the analyses were to identify
markers speciﬁc to fatigue that are also possibly exclusive to CFS. The use of such models can be motivated,
for example, by the search for new biomarkers for the diagnosis and prognosis of cancer and measures of
response to therapy. Generally, for this we use Bayesian hierarchical modeling and Markov Chain Monte Carlo
computation.
© 2008 Elsevier Inc. All rights reserved.IntroductionFinding genetic biomarkers and searching the whole genome for
genetic–epidemiological predisposing factors can both be formulated
as a statistical problem of variable selection, inwhich a tiny number of
trait-associated predictors (measurements from the genome) is
selected from a large set of candidates [1–3]. Statistical variable
selection plays an important role in personalized medicine [4] and in
the development of models to predict disease state or drug response
in humans, and it is the ﬁrst step in marker-assisted selection
programs in plant and animal breeding. Moreover, statistical variable
selection methods are also essential in studies of cancer biology,
immunogenetics, neurogenetics, behavior genetics, toxicology, and
gastroenterology, which may like to use different crossing designs of
mouse or rat data (animal models of human disease). In any case, the
search for new biomarkers for the diagnosis and prognosis cancer and
measures of response to therapy is already providing sufﬁcient
motivation for modern statistical and computational work.
Chronic fatigue syndrome
We will illustrate our method using an extensive analysis of a
large data set related to chronic fatigue syndrome (CFS). CFS is acharjee).
l rights reserved.complex disease with a wide spectrum of physiological and
psychological characteristics. The predominant feature of this
disorder is deep and persistent fatigue with several other severe
symptoms such as temporary memory loss, severe headache, and
mental disorders. It remains a major challenge in modern genetics,
since CFS has no diagnostic signs, tests, or risk factors that have been
conﬁrmed by scientiﬁc studies. The unfortunate consequence of this
is a lack of a deﬁnitive treatment for this disorder. Efforts have been
made to outline rigorous guidelines for diagnosing the disease, ﬁrst
in 1994 and subsequently in 2003. We will be following the latter
proposal of case deﬁnition of CFS given in [5]. It is believed that
diseases like CFS are a manifestation of combined effects of genetic
and environmental factors. By using some of the key advancements
in biotechnology, such as microarray-based gene expression and
MALDI-TOF-based protein expression information, we attempt to
identify some of these factors. This will be done together with more
traditional genetic and clinical data.
Bayesian biomarker identiﬁcation
Bayesian methods are used regularly now in the analysis of high-
throughput bioinformatics data coming from medical research and
molecular and structural biology. Among the many advantages of this
framework, one of its main utilities is that evidence can be easily and
ﬂexibly incorporated into statistical models. Prior information such as
distance between markers, which causes dependence in genetic
studies, can be accounted for by stochastic processes in association
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raw measurements and/or dependence induced by normalization can
also be addressed in this framework. Thus we propose to use Bayesian
hierarchical models for the diverse data available for CFS, wherein
each item will be analyzed thoroughly, leaving possibilities for
prediction and integrated analysis. Another inherent property of this
setup is coherent probabilistic propagation of error. As is well known,
the analysis of most high-throughput data requires multiple decision-
making steps. In a Bayesian setup it is possible to use, instead of
degenerate observations, joint posterior distribution of objects (like
genes and proteins) by which the distribution reﬂects uncertainty in
the earlier analyses steps (e.g., normalization or peak identiﬁcation).
Integrated inference
It should be mentioned here that in translational medicine it
would be desirable to be able to derive integrated predictive models
based on all available information jointly. However, the underlying
disease mechanism for CFS is far too complex to be expressed
satisfactorily through a single comprehensive model. Our previous
experience of analyzing these data conﬁrms the same [6]. Thus here
we ﬁrst derive, for each type of experimental data, models based on
variable selection methods. The primary objective of these models is
to provide sound robustness in biomarker identiﬁcation. This is
achieved by careful propagation of error in decision making in various
steps of analyses. The biomarkers thus identiﬁed would then be
further investigated using available database information to identify
possible biological connections between the markers/genes identiﬁed
from different data types. This would be carried out in multiple ways,
both within data type consistency (compared with existing knowl-
edge) and across data type consistency (of biomarkers as obtained
from the different data types by our models).
Data considered
The data used here for illustration were made available by the
Center for Disease Control in Wichita, Kansas, USA. A wide range of
data was generated to help researchers study this complex disease. As
a part of the Critical Assessment of Microarray Data Analysis (CAMDA)
competitions in 2006 and 2007 CFS data were made available to the
public in two phases. We used the second phase of data, which is
signiﬁcantly larger than the ﬁrst and has been studied by very few.
These data sets and relevant references (including our previous work)
can be found on the CAMDAWeb sites (http://www.camda.duke.edu/
camda06/datasets/ and http://camda.bioinfo.cipf.es/).
Phenotype data
In the original paper by Reeves et al. [5] the “Empiric” variable was
proposed as a comprehensive empirical summary of the disease
symptoms. In the same article it was reported that principal components
analysis of the 14 major symptom scores yielded three principal
components accounting for 76% of the variation. Further these three
components cleanly separate the three relevant empiric classes, viz. Non-
fatigued (NF), Insufﬁcient symptoms of fatigue (ISF) and CFS. Therefore
this phenotype can be seen as a linear combination of clinical variables.
Therefore we selected the Empiric variable as indicative of disease
status of the study individuals and according to this there were 58
individuals with NF, 59 with ISF, and 43 with CFS in the data. Our
primary objective was to identify genetic and biomarkers critically
different between the CFS and the NF individuals. We also wanted to
assess if some of these were exclusive to CFS or shared with other
fatigue-related diseases (as captured by the ISF individuals).
The clinical data available for this study consist of many
epidemiological and symptom variables. These potentially could be
used as covariates. However, for most of these variables it was notevident that their effects could be counted as additive/multiplicative
factors, as is typically done with such covariates. Therefore a selected
few were taken and used mostly for the purpose of homogeneous
stratiﬁcation of genetic effects in the data (i.e., to study strata-speciﬁc
genetic effects).
Marker data
The marker data available in this study were mostly single-
nucleotide polymorphisms (SNPs). As we know, SNPs are single base
changes in the DNA causing natural sequence variations in humans. It
is believed that such variation could provide crucial insight into
disease outcome. We genotyped, on 222 individuals, 168 SNPs
pertaining to 39 genes. Many of these genes are known to be involved
in the neurotransmission system, and mutations in these genes can
lead to mood disorders. Some of the other genes are involved in the
neuroendocrine system. Disturbance of this system leads to various
psychiatric illnesses such as anxiety, depression, intolerance to stress,
and sleep disturbance. Details of the DNA extraction and genotyping
method have been reported in [7].
We obtained location information for both gene regions and the
SNPs within them. This potentially can increase inferential powers by
using models proposed in literature [1,2]. Such models account for
possible dependence of behavior between two closely placed SNPs
and can identify dependence structure.
Expression data
Unfortunately, in CFS, the pathologic lesion is unknown, so a
speciﬁc disease sample cannot be studied. To examine global gene
expression to determine if this molecular approach can be used to
distinguish between individuals (cases) with CFS, peripheral blood
mononuclear cells were used as biological samples [8]. Themicroarray
technology used to gather data was the MWG 40K microarray,
consisting of two glass slides (A and B), each with 20,000 features
representing human genes. Gene expression data only for microarray
slide A was available for analysis.
In total, microarray experiments were carried out on 177 arrays, of
which 164 were used for further analysis after carrying out quality
checks. Cutoff intensity was set at 100. Spots were checked for missing
data and only spots with at least 20 arrays with data for each Empiric
group (viz. NF, ISF, CFS, and Other) were selected for analysis. Thus of
20,160 spots, only 9953 met this criterion and were used. As was done
for the SNP data, for the microarray data we gathered additional
information on the locations of the genes and selected functionalities,
pathways, etc.
Proteomics data
From the same CFS study a preprocessed proteomics data set was
made available on 206 subjects. Because of the high number of
missing data we had to exclude several subjects, so data from 164
subjects were used for analysis. The data contain three measurements
arising from three different ProteinChip array chemistries, reversed
phase (H50), metal afﬁnity capture (IMAC30), and weak cation
exchange (CM10), each at two laser intensities. This resulted in
895 m/z values (in different fractions), and in several cases the same
m/z values were observed in different fractions. Because the pI’s of
these proteins were different, even though their mass could be similar,
suchm/z’swere treated as distinct. The otherm/z values that appeared
in different array types at the same fraction were also treated as
different since fractionation provides only a rough estimate of the pI.
While SELDI data are ideal for proﬁling protein expression levels to
determine patterns of expression that are associated with particular
disease states [9], they cannot be used on their own to identify
biomarkers for CFS. SELDI reports only the peptide/protein molecular
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two counts. (1) SELDI molecular weight measurements (essentially
MALDI-TOFmassmeasurements) are not accurate enough to identify a
protein uniquely. (2) At present there is not a complete enough
knowledge of the posttranslational modiﬁcations that occur, e.g., in
the human body, to produce a database of all the masses one would
expect to ﬁnd, for example, in serum. SwissProt goes someway toward
this by documenting the information known about signal sequences
and propeptides removed posttranslationally. This information is used
by our program of choice for searching for proteins of a given mass,
ExPASy’s TagIdent [10], before computing pI and Mw for each of the
resulting chains. However, this does not address modiﬁcations that
add to the mass of the protein, e.g., phosphorylation or glycosylation.
However, in the absence of any other means of combining these
data with the rest of the data we used predicted genes corresponding
to themass and pI information. Thesewere then used to obtain similar
annotations as SNP and microarray data. One possible objective could
be to assess chromosome region enrichment (genomic overlap)
between the suggested locations from different analyses [11].
Inferred and database data
In the overall analysis the data come from a varied source and are
schematically presented in Fig. 1. The current practice of handling
multiple experimental data or multiple analytic steps would be to
work with very crude summaries, e.g., a list of differential (or
otherwise interesting) genes, ignoring the fact that almost always
such lists are the outcome of decision making and decisions were not
taken with 100% conﬁdence. We believe some associated measure of
conﬁdence should be utilized.
Moreover, in some aspects of analysis such summarization is
potentially misleading. For example, many have experienced that
normalization affects subsequent biological conclusions from a
microarray data analysis. One solution would be to carry out model-
based normalization and use the joint distribution of the (distinct)
genes for further analysis. Similarly, while integrating gene character-
istics from one experiment to another the joint distribution of genes
with respect to the (conditioning) characteristic could be used in the
subsequent experiment.
Such probabilistic summarization is denoted as inferred data and it
reﬂects our knowledge of and conﬁdence in the data. The best possible
use of one source of data would be using the joint distribution of all
parameters of interest; if that is too large or complex then a summary
(possibly the ﬁrst two marginal moments for each feature) can be
used. In some situations we might have to use the categorical
(typically binary) summarization of a data.Fig. 1. Schematic presentation of all data sThe Web addresses of some of the Web-based databases and tools
we have used are in the supplementary materials.
Statistical models and estimation
Handling of missing values
In general, we assume missing at random, meaning that the
missing-data mechanism is independent of the value of the element
itself conditional on a set of auxiliary variables or known covariates. In
the association analyses models, we used Bayesian Data Augmenta-
tion Model 2 of [1] as prior for genotypes to handle missing values. In
case there were values missing in the stratifying variables the
augmentation was carried out using posterior frequency distribution
resulting from Uniform–Bernoulli prior assumption on the respective
distribution.
For expression analysis the missing values are augmented through
the integrated model for normalization and differential analysis [11].
The augmentation is thus based on information of the location of a
gene on the array, information about the expression behavior of other
neighboring genes, and the expression pattern of the same gene on
other arrays and also the overall expression pattern of all individuals
in the relevant treatment group.
Typically a missing-data situation for microarrays is handled in
twoways. The ﬁrst is to omit the corresponding gene entirely from the
analysis, resulting in a huge loss of information. The second and more
commonly adopted approach is to decide a “ﬂoor,” e.g., 100, and all
observations below this will be modiﬁed to this ﬂoor value. In our
approach we treat values below 100 as missing but augmentation is
random around its predicted mean. For proteomics data a similar
model-based data augmentation is carried out.
Propagation of uncertainty: An added advantage of the Bayesian
framework is that the inference on parameters of interest is carried
out jointly with integrating out the missing data. Thus uncertainty
in augmenting the missing value as captured by the model is
accounted for in the ﬁnal conclusions. In contrast most computa-
tional approaches augment or systematically replace missing data
with ﬁxed values, if partially observed data are at all considered. In
theory missing data augmentation is a topic of interest to many,
but in practice (in particular for high-throughput data) it is rarely
given any consideration.
Association analysis
The Bayesian association mapping models utilize the location
information of the M gene regions and the SNPs within them. Theseources used for integrated modeling.
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model is based on indicator variables (denoted as Il for gene region l)
controlling inclusion/exclusion of the genetic effects from the model.
Note that CFS and IFS categories are not treated with equal importance
here. These models were primarily applied to identify SNPs associated
with CFS, found by contrasting the NF and CFS categories, and
secondarily to ﬁnd a subset of those that are neutral with respect to
ISF. For binary outcomes (see [6]), contrasting the NF and CFS
categories, a logistic association model for SNP data (of individual i)
can be written as
logit pið Þ ¼ aþ
XM
l¼1
XNl
s¼1
Il  βl;sg1i;l;s þ βl;sg2i;l;s
  
:
Here logit pið Þ ¼ ln pi1−pi
h i
¼ ln P yi¼1jg;xð Þ1−P yi¼1jg;xð Þ
h i
, a is an overall mean para-
meter, βl,s is an effect size of the second allele of SNP s at gene region l,
and Nl is the number of SNPs at region l. The collected marker data in
each SNP (l,s) are represented using allele codes (g1i,l,s, g2i,l,s), which
equal 0 (if allele type=1) or 1 (if allele type=2), depending on their
allele type.
A Markov-dependence model, similar to that in [1], was used to
describe the dependence (covariance) between the SNPs according to
their (physical) map distance, a smoothing parameter, and a
stringency parameter describing the essentials of the model. In the
model, marker signals are smoothed to account for covariance
between markers and to reduce spurious associations/ﬂuctuations in
the data. The shrinkage parameter can be interpreted as the prior
probability of selecting a candidate variable (that is, the corresponding
indicator is one) in the model.
Stratiﬁcation was carried out using only one of the selected few
variables at a time, like onset and gender, for which stratiﬁcation
carries a meaningful interpretation in the context of this disease apart
from reducing variability. A full stratiﬁcation could mean possible loss
of power due to smaller sample size. Therefore we implemented
stratiﬁcation in the space of phenotypic effects that share common
variance parameters over strata to prevent such loss of power.
The selection probability: Further to the development of themethod
we obtained an estimate of the null distribution of the weighted
genetic variations under all possible distances between SNPs for a
problem of the current size. This distribution can then be used to carry
out a Bayesian test on the signiﬁcance of the SNPs for current analysis.
However, the estimate actually provided a conservative assessment of
the percentiles, and hence a less stringent cutoff percentile was used
to identify relevant SNPs.
Expression analysis
The arrays generating the expression data are from single-channel
experiments; however, we have noted a visible departure from
linearity across arrays very similar to that observed in two-color
microarray experiments. We propose to normalize each array with
respect to the vector of spot-level overall average.
The normalization was done using the block-level piecewise
linear-regression normalization method of [11] (assuming known
knot points). The distribution of log intensity of gene expression
(denoted by LIElij) has been speciﬁed accordingly. The piecewise
linearity is implemented through the intercept and scale parameters
over the (log) intensity “window” parameter (denoted by w(lij)).
Further, connectedness was ensured by putting constraints on the
intercept parameters (i.e., α’s). Therefore for every array and every
block, parameters necessary for carrying out ﬁve-piece-connected
Bayesian linear regression were utilized in modeling the (log)
intensity measurements. The parameters involved in the normal-
ization part of the model are denoted by:
βljkm ∼N 1; 0:1ð Þ andαljk1 ∼N 1;0:1ð Þ;where
αljk2 ¼ αljk2 þ βljk1−βljk2
  6;
αljk3 ¼ αljk2 þ βljk2−βljk3
  7;
αljk4 ¼ αljk2 þ βljk3−βljk4
  8;
αljk5 ¼ αljk2 þ βljk4−βljk5
  9;
l is the empiric category, j is the array, k=1, …, 48 (blocks on each
array), and m=1, 2, …, 5 (number of windows/pieces).
The observed average intensities over all arrays for each spot
(denoted by avgi below) were used to normalize all the arrays. This
can also be thought of as utilizing the data at a hyper-hyperpara-
meter level, at which the mean of each gene for each disease
category (say, θ1ki) is drawn from a gene-speciﬁc parameter (say θ0i ),
which in turn is described by a normal distribution with given mean
as overall sample average.
Propagation of uncertainty: This model actually produces a joint
distribution of the normalized intensities, in which posterior means
are comparable to Lowess normalized values. This distribution
reﬂects the reliability/our conﬁdence in these normalized values.
This feature is not available in Lowess or other computational
methods or even most statistical methods. We use this posterior
distribution to carry out the subsequent (differential) expression
analysis. This enables us to propagate fully the normalization
uncertainty in the gene selection procedure.
We assume that, a priori, every gene i has its own level of
expression ratio, say θ0i, where θ0k∼N(0, 0.1), with k=1, …, number of
distinct genes.
Let the expression for the lth empiric category be θ1li, where θ1li are
assumed to be drawn from a normal distribution with mean θ0i :
LIElij ∼N αljb ið Þw lijð Þ þ βljb ið Þw lijð Þ avgi þ θ1ld ið Þ
  
;τ1ld ið Þ
 
;
where
θ1lk ∼Normal θ
0
k ; τ
0
k
 
;
τ0k ∼Gamma 1;1ð Þ;
τ1lk ∼Gamma 1;1ð Þ;
l is the empiric category, i is the spot, j is the array, b(i) is the block on
array inwhich the ith spot is located,w(lij) is the intensity window for
the lijth observation (as explained above), and d(i) is the distinct gene
corresponding to the ith spot on the array.
A joint normalization and expression analysis was done, followed by a
regularized two-sample Bayesian t test [12,13] to identify relevant genes.
We have noted in our earlierwork that posterior estimates of probability of
differential expression as obtained here compare very similarly to those
obtainedbywell-knownSAM(SigniﬁcantAnalysis ofMicroarrays) analysis.
Also the spirit of this joint normalization and expression analysis is
comparable to RMA (Robust Multichip Analysis) and ANOVA approaches.
Thus thenoveltyof this approachbecomesclearwhenwesee thatposterior
summaries from our method produce results similar to these popular
methods; additionally the whole joint posterior remains available in our
method and can be used for numerous other purposes such as assessing
any parameter/hypothesis, quantifying our conﬁdence, etc.
Proteomics analysis
The principal outcome required from these data is very similar to
that of identifying differentially expressed genes. Hence a model
similar to the above (without the normalization factors) was used to
analyze these data at a ﬁrst level. Here also a Bayesian t test was used
for preliminary identiﬁcation of differential protein masses. The joint
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into a second-level model (and smoothed if necessary with the
between-m/z distances). The use of joint posterior ensures that even if
a protein is only marginally important it will still contribute to the
second-level model.
The peaks in the protein spectra may occur as a real observed
intensity difference between two groups, diseased (CFS) and healthy
(NF) individuals. However, because of noise, some differential peaks
may be spurious and occur as a consequence of some other factor than
the real change in the disease state. Potential reasons for spurious
peaks include measurement errors and inaccuracies in alignment.
Thus, to control for spurious peaks (false signals), the smoothing of
peaks with respect to neighboring locations has been proposed for
proteomic proﬁling [14]. We present here the new smoothing
approach based on two-level hierarchical modeling. The use of
hierarchical modeling for subset selection and for closer inspection
of the most promising candidates in a genomewide association study
context has recently been proposed by Chen and Whitte [15]. A two-
level model is also considered here so that the ﬁrst level feeds in
candidates for the second level, where the smoothing of intensity
peaks with respect to neighboring locations (at the same m/z region)
is done according to m/z distance between the positions [1]. For each
m/z ratio, the ﬁrst-level model checks whether corresponding
intensity is marginally differentially expressed between CFS and NF
(similarly for ISF and NF). In the second-level model, a logistic
regression is performed jointly with all the differential peaks usingm/
z distance and smoothing. This way multiple signals from the samem/
z region due to measurement error, inaccuracy in alignment, etc., will
be adjusted and overall signals can be identiﬁed. Note that in additionFig. 2. Gender-speciﬁc effects of SNPs on chromosometo adjusting the dependence between neighboring m/z’s, the joint
explanation of m/z’s with respect to phenotype is also accounted for.
Propagation of uncertainty:These two parts are modeled simulta-
neously in the single hierarchical structure, so in a differentMarkov Chain
Monte Carlo (MCMC) iteration we would be proposing different sets of
candidates (m/z values) as differentially expressed. Thiswaywe can adjust
for decision errors due to variable/feature selection and missing values.
Although the two-level model will be implemented as one large
hierarchical structure, actually we want to treat them as two separate
models. Technically we use the “cut” function inWinBUGS [16] to stop
feedback from the second-level model to the ﬁrst-level model. The
reason for this is that the phenotype data are used twice (in both levels
of model) and intensity data partly twice, which will bias some
credible intervals if the “cut” function is not used.
Integrated analysis
In our previous analyses [6] the objective was to form an all-
encompassing integrated model inwhich clinical, SNP, and expression
data would be used. First, this restricted us to utilizing data only on
those individuals on whom all such data were available. Moreover we
also learned from that analysis that only expression showed some
effect in the joint analysis. Generally, it is likely that continuous
expression measurements contain more information than discrete
SNP markers. This property may be more noticeable when individual
effect sizes are very small. Thus it may look like expressions “override”
markers, even if in reality marker effects of the joint model are too
small to be detectable given the size of the current data sets. Another
possible reason is that expressions and markers involved in the sames 5 and 1 in disease-marker association analysis.
Table 1
Genes showing high association with CFS when analyzed using expression data for CFS
and NF individuals
Rank Gene Location Rank Gene Location
1 TACC2 10q26 11 DRG2 17p11.2
2 CDK7 5q12.1 12 MKX 10p12.1
3 C2orf56 2p22.2 13 SARDH 9q33-q34
4 PLAT 8p12 14 HSPA1L 6p21.3
5 EPHB2 1p36.1-p35 15 GNL1 6p21.3
6 CNRIP1 2p14 16 APBA2 15q11-q12
7 SIRT5 6p23 17 CFLAR 2q33-q34
8 PURB 7p13 18 NEK6 9q33.3-q34.11
9 BTK Xq21.33-q22 19 RUNX2 6p21
10 ZFY Yp11.3 20 HTRA1 10q26.3
Fig. 3. Estimated selection probabilities under stringent tests form/z values (for pI=3 at
the top and pI=9 at the bottom).
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among such predictors (see the Discussion).
Thus in this analysis we did not attempt to form such an overall
integrated model for the data; however, we intended to provide an
integrated prediction of relevant (biological and genetic)markers for the
disease from individual data types. Here we would ﬁrst carry out
biomarker identiﬁcation using the models described in the previous
sections. We would then investigate them further using available
database information to identify possible biological connections
between the markers/genes identiﬁed from the different data types.
We would do this in multiple ways, both within data type consistency
(compared with existing knowledge) and across data type consistency
(of biomarkers as obtained from the different data types by ourmodels).
Computational aspects
MCMC samples
In all cases, the posterior (median) point estimates were based on
at least 5000 MCMC samples. However, note that ﬁrst, Monte Carlo
errors would be reasonably small even with much smaller MCMC
samples and second, if the objective is to use only the ﬁrst two
moments from posteriors they can be reliably estimated with small
MCMC samples up to a choice of accuracy.
Burn-in and convergence
Typically two parallel MCMC chains were run. The length of the
burn-in period for different models varied depending on which
MCMC samplers were being used and the speed of convergence.
WinBUGS software provides diagnostic tools for checking the
convergence. Additionally, visual checks for individual parameters
are extremely useful.
Initial values and stepwise implementation
At the early steps of implementation, initial values for some of the
key parameters were chosen to be as different as possible, and others
were generated directly from their priors. At subsequent steps,
different choices were made for different subsets of parameters for
initial values. In stepwise cumulative implementation of the models,
initial values were generated using posterior distributions if available
from a previous step. This enables us to validate various things, such as
whether the cumulative models are performing consistently or
whether there are identiﬁability problems. Also the between-step
consistency, as described above, proves crucial in the parameteriza-
tion of the subsequent models.
Choice of priors and hyperparameters
The distributions used are the most intuitive distributions for such
types of data. These distributions are well known, reasonably general,
and computationally viable. The choices of (hyper) parameters were
made typically to generate a vague prior, meaning a ﬂat distribution,
for example, all the normal distributions for priors in the expression
data modeling have variance 10. Where we do use an informativeprior, like the gamma distribution for τ, it is done after carefully
carrying out a sensitivity analysis.
Selection probability
As is the common practice in Bayesian methods, conﬁdence is
expressed as a posterior percentile instead of the signiﬁcance. It refers
to the posterior probability of crossing a threshold (typically a critical
value of a statistic, such as t). For expression and proteomics data a
typical threshold will be an appropriate t-statistic critical value (and
we have used 95% throughout). For genotype data, lower critical
values were used, as discussed before.
Codes
The WinBUGS model speciﬁcation codes for association analysis
are already available at http://www.mcs.st-andrews.ac.uk/~madhu/.
WinBUGS codes for remaining analyses will be made available at the
same Web site.
Results
SNP analyses
It was noted previously that stratiﬁed/subset analysis improves
our ability to ﬁnd associations. It is not uncommon, behind a
complex disease, for the genetic mechanism to vary across subsets of
individuals. For example, when the clinical variable “Gender” was
used, a noticeable association with the disease status was exhibited
by some SNPs. With the current data, which are much more
numerous than previously, we attempted a similar analysis. Quite
encouragingly there was much consistency noticed between our
previous analysis results and those obtained based on the current
data. Note that although we are carrying out strata-level modeling
we actually are not losing power in identifying SNPs that are
signiﬁcant irrespective of strata.
By using distance to model dependence between closely situated
SNPs in a region, we can accurately identify the SNPs showing the
most variation in the disease groups. The gene region NR3C1 was
found to be signiﬁcant and it continued to be so. The SNP found is
different from that found by the analysis without distance; however,
the magnitude of variation remained quite comparable, which is
highly signiﬁcant since now these SNPs are identiﬁed among a much
larger group of SNPs selected through a harder competition. Similarly,
Table 2
Some top selected m/z values and their corresponding putative predicted genes
Observed data Predicted data
pI m/z Entry name Acc. No. pI mw Location
9 12794 TGFB1_HUMAN P01137 8.59 12795 19q13.2
5 6609 Q7Z6N2_HUMAN Q7Z6N2 5.14 6606 5q23-q31
9 12806 C11orf67_HUMAN Q9H7C9-2 9.06 12807 11q14.1
4 9381 WDR75_HUMAN Q05D27 4.37 9398 2q32.2
4 17152 ABHD1_HUMAN Q96SE0-2 4.35 17121 2p23.3
9 3258 PCMTD1_HUMAN Q9HAZ8 9.18 3227 8q11.23
5 8208 PSCA_HUMAN O43653 4.51 8219 8q24.3
5 6413 Q9P168_HUMAN Q9P168 5.31 6409
5 3181 SNRPA1_HUMAN Q9UEN1 4.94 3205 15q26.3
4 13799 SART3_HUMAN Q15020-3 4.23 13773 12q24.1
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showed up in both analyses.
Weighted genetic variance
We used weighted genetic variance for each location as a summary
statistic. This is a model-averaged posterior estimate of genetic variance
calculated as the product of the indicator variable times the variance (or
absolute difference) of allelic effects for the SNP level (or for SNP at
strata level) estimate [1,2]. Weighted genetic variances of all SNPs on
chromosome 5 are plotted for each stratum in Fig. 2. Note that two
particular SNPs of NR3C1 (hCV11159943 and hCV11837659)were highly
relevant for both female and male strata while discriminating between
CFS and NF individuals. In fact, these two SNPs indicated signiﬁcant
allele frequency differences between fatigued (CFS or CFS plus ISF) and
NF subjects also in the study of Rajeevan et al. [17]. As expected, we can
identify SNPs that are speciﬁc to a stratum, for example, HTR6 on
chromosome 1 is highly signiﬁcant in the male stratum (see Fig. 2).
Allele frequency study
Similarly, comparing ISF and CFS (while also comparing with NF
individuals) we obtained signiﬁcant SNPs, such as HTR2C-hCV339374,
discriminating the subjects. However, the mechanism is quite
different between the two disease categories, with roles (or
frequencies) of the alleles reversed in CFS and ISF compared to NF.
For the BDNF gene the SNP hCV12035465 has only a G allele in the
male stratum for individuals with CFS, hence this is signiﬁcant for the
NF–CFS study in this stratum; additionally, the G allele proportion in
male ISF is much lower than in the male NF population, making it alsoTable 3
Examples of genomic regions supported by multiple data sources
Data Symbol Location Data Symbol
Expression BSDC1 1p35.1 Expression UBE2V2
Expression PRKACB 1p36.1 Proteomics PCMTD1
Expression USP48 1p36.12 Proteomics JRK/PSCA
Expression ARHGEF10L 1p36.13 Expression LOC5123
Expression EPHB2 1p36.1-p35 Expression SIRT3
SNP HTR6 1p36-p35 SNP TH
Expression GCKR 2p23 Expression APOA5
Expression NCOA1 2p23 SNP DRD2
Proteomics ABHD1 2p23.3 Expression MLL
Expression POMC 2p23.3 SNP HTR3A
Expression GLI2 2q14 SNP HTR3A
SNP IL1A 2q14 SNP HTR3A
SNP IL1A 2q14 SNP HTR3B
Expression DNAJC10 2q32.1 Expression ARHGEF1
Proteomics WDR75 2q32.2 Expression SCN3B
Expression PPP3CA 4q21-q24 Expression USP2
SNP SPP1 4q21-q25 SNP IFNG
Proteomics MGC29506 5q23-q31 Expression WIF1
Expression PCDHA10 5q31 Expression PEX11A
Expression NDFIP1 5q31.3 Expression LOC1457
SNP NR3C1 5q31.3 Proteomics SNRPA1
SNP ACE
Expression ACErelevant in the ISF–NF comparison. Note again that the behavior of the
SNP is opposite in the CFS and ISF cases. Thus, several SNPswere found
to show the association signals in this analysis.
Heterozygosity analysis
SPP1-rs11730582 on 4q21–q25 was identiﬁed as a SNP relevant for
the male stratum discriminating NF–ISF–CFS. The estimated hetero-
zygosity at different (sub)population levels for this SNP is as follows:
population 0.42, whole CFS data 0.53, all CFS individuals 0.56, female
CFS individuals 0.50, and male CFS individuals 0.86. This further
conﬁrms our model ﬁnding.
SNP functional analysis
From the F-SNP database we integrated information on the
functional effects of SNPs. The four categories covered by this database
are (1) protein coding, (2) splicing regulation, (3) transcriptional
regulation, and (4) posttranslation. In terms of magnitude the
variation in the CFS-related SNPs that were also protein-coding or
transcriptional-regulation related was signiﬁcantly higher than
average. Unfortunately we were unable to locate any further
functional information at the SNP level. Such information is available
sporadically but not for all SNPs to carry out any statistical analysis.
Expression analyses
Based on gene-expression data analysis as described before,
several genes were identiﬁed as strongly signiﬁcant. Some of these
are presented in Table 1, in which the top genes selected based on
Bayesian t test for comparing CFS and NF individuals are reported.
Similar to the SNP-data analysis, here also we can compare genes that
are potentially exclusive to CFS compared to their expression pattern
in ISF individuals (result not reported).
Pathway analysis: The top pathways related to the signiﬁcant genes
are the MAPK signaling pathway, neuroactive ligand–receptor inter-
action, axon guidance, regulation of actin cytoskeleton, apoptosis,
insulin signaling pathway, cell cycle, and calcium signaling pathway.
Proteomics analyses
The Bayesian t test of the proteomics data, while identifying CFS-
speciﬁc m/z values, produced some reasonably high but not many
signiﬁcant results. A less stringent test obviously picks up moreLocation Data Symbol Location
8q11.21 Expression USHBP1 19p13
8q11.23 Expression TMEM16H 19p13.11
8q24.3 Expression TMEM38A 19p13.11
6 8q24.3 Expression PKN1 19p13.1-p12
11p15.5 Expression PRDX2 19p13.2
11p15.5 Expression TNFSF14 19p13.3
11q23 Expression ZNF14 19p13.3-p13.2
11q23 Expression CEBPA 19q13.1
11q23 Expression LRFN3 19q13.12
11q23.1 Expression PRX 19q13.13-q13.2
11q23.1 Expression CD79A 19q13.2
11q23.1 Expression PVRL2 19q13.2
11q23.1 Proteomics TGFB1 19q13.2|19q13.1
2 11q23.3 Expression AKT1S1 19q13.33
11q23.3 Expression BBC3 19q13.3-q13.4
11q23.3 Expression TNNI3 19q13.4
12q14 Expression TTYH1 19q13.4
12q14.3 Expression LOC147804 19q13.41
15q26.1 Expression AKAP4 Xp11.2
57 15q26.3 SNP MAOA Xp11.3
15q26.3 Expression MED14 Xp11.4-p11.2
17q23.3
17q23.3
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probabilities (under stringent tests) are presented for different pI
values and all m/z values covered in the data.
Gene prediction: For the proteomics data, using TagIdent soft-
ware we predicted genes for as many possible m/z values at
relevant pI levels as possible using a stringent tolerance level (Table
2). The clear biological relevance of some of these predictions
indicates a good possibility of corresponding proteins being present
in the CFS samples.
Integrated analyses
The detailed study of the expression data itself can help to identify
possible factors behind this syndrome. However, due to its larger size
compared to the other data sources, viz. SNP and proteomics data, the
expression data set tends to dominate the ﬁndings of such integrated
analysis. Our previous experiences of analyzing CFS data and other
such diverse data sets have been similar. Therefore in the current
analysis wewill focus on several relevant pathways and other features
(like genomic regions) and integrate information from all sources to
assess enrichment [11].
For each gene we now utilized its selection probabilities from SNP,
microarray, and proteomics data analyses. We used these on the
genome level to identify possible gene regions (Table 3) or functional
enrichments. We then used these for a variety of analyses. On
chromosome 17, the region 17q21–23 showed up several times based
on different data, implying important that genetic markers and
biomarkers could be present in this segment. Incidentally in our
previous analysis, also, this region was found important. One such
example is the ACE gene on 17q23.
The ACE gene was found to be signiﬁcant based on both
expression data and SNP data. This is critical since the gene ACE
appears relevant not only from a functional point of view (based on
expression data) but also in structural variation (as indicated by the
SNP data). It is highly unlikely that the correlated behavior of this
gene in both SNP and expression data would be spurious. This gene,
along with other genes on our combined list of signiﬁcant genes, is
involved in the renin–angiotensin pathway. However, polymorph-
isms in the ACE gene are also known to be associated with unipolar
depression, ACE activity, and hypercortisolism [18]. It has also been
found to be associated with CFS based on a study of Gulf War
veterans [19].
Discussion
We have formulated the problem of identifying trait-associated
genetic components and biomarkers in the framework of Bayesian
variable selection. For each individual data type we have utilized
advanced modeling techniques. These we have implemented on a
much larger data set than before. Wherever comparisons could be
made with previous ﬁndings these were done and results were
consistent. Our analyses also included some novel modeling and
inference approaches; for example, the two-stage modeling of the
proteomics data with smoothing using m/z distance is new to our
knowledge.
While analyzing using existingmodels, quite oftenwe observe that
even moderate change in analysis technique for one data set and for
any single step of analysis can inﬂuence overall biological conclusions.
It is well known that this happens owing to not propagating
uncertainties in these analysis steps to subsequent steps. Our
modeling setup has this important advantage, that an integrated
analysis of all data types and all steps of analysis can actually be
implemented within a single model and inference framework. This
enables systematic propagation of uncertainty in analysis of individual
data sets and at the same time provides a comprehensive genome/
functional level summarization of information in data. We haveimplemented similar large-scale Bayesian integrated modeling for
other real problems, such as in a cancer study [20].
The colinearity (dependence) of the markers due to (1) the close
proximity along the chromosome or (2) the shared pathway member-
ship (present also among expressions) induces problems in a multiple
testing framework, because asymptotics do not hold for dependent
tests. Also the number of tests quickly become very large, making
control of false positives very difﬁcult (for dependent tests) despite
the use of methods such as false detection rate. Again collecting more
data or the use of meta-analysis (combining several data sets
together) may help, but that introduces its own problems for
statistical analysis [21]. In the Bayesian framework, we rely on
parameter estimation rather than hypothesis testing, which makes it
possible to avoid multiple testing problems. Also, the parameter
estimation and model selection are often done simultaneously when
dependencies of the data can be modeled explicitly [22].
The composite data we consider for this analysis comprise data
from several experiments, which are meaningful and complete by
themselves. These were then augmented with the data from a
multitude of databases available now. The biological hypotheses were
translated in a statistical framework as functions of parameters (e.g.,
expression) and were assessed a posteriori. The different functional
combinations of the model parameters cover a wide range of
biological characteristics to be studied. This is another aspect of our
modeling setup that is not easily available in the commonly used
statistical tools, simply because complex hypotheses would require
specialized testing procedures that may not be available readily. The
complexity of individual modeling units was kept moderate to
optimize computation time and parameter space of interest.
Analytic intractability is a common consequence of such complex
models. We have to admit that implementing such models has not been
easy. On standalone computers someof thesemodels take 1GBof RAMto
run; someof these also take considerable time for theMCMC iterations. In
this respect an achievement worth mentioning here is being able to
implement these models on standard Bayesian software like WinBUGS,
thus enabling us to implement numerous modeling options (for varied
input data types) without having to create custom codes. Thismakes this
method repeatable on demand and extendable if required.
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